Peptamen® AF (n = 46) | Isosource® Energy (n = 44) | |||
---|---|---|---|---|
Age, years | n = 46 | 65.3 (52.6–75.3) | n = 44 | 61.6 (48.6–71.3) |
Sex, male | n = 46 | 33 (72%) | n = 44 | 28 (64%) |
Body mass index, kg/m2 | n = 41 | 28.8 (25.1–34.2) | n = 41 | 27.8 (23.5–31.5) |
APACHE II admission diagnosis | n = 44 | 28.5 (22.3–32.8) | n = 42 | 27.5 (22.0–33.3) |
SAPS II admission diagnosis | n = 46 | 60.5 (46.5–74.0) | n = 44 | 61.5 (48.5–75.5) |
SOFA | n = 45 | 8.0 (6.0–11.0) | n = 44 | 7.0 (5.0–10.0) |
Mechanical ventilation | n = 46 | 43 (94%) | n = 44 | 43 (98%) |
Treated with vasoactive drugs | n = 46 | 31 (67%) | n = 44 | 29 (66%) |
Diabetes | n = 46 | 13 (28%) | n = 44 | 8 (18%) |
Residual gastric volume at study inclusion, ml | n = 42 | 35.0 (10.0–112.5) | n = 43 | 50.0 (20.0–100.0) |
Presence of diarrhea at study inclusion | n = 46 | 5 (11%) | n = 44 | 4 (9%) |
Blood glucose at study inclusion, mmol/l | n = 46 | 7.8 (6.8–8.9) | n = 44 | 8.3 (6.9–9.4) |